En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
INNOSUISSE
Numéro de projet
15523.1 PFLS-LS
Titre du projet
Preparation of enantiopure antimalarial agent (+)-mefloquine
Titre du projet anglais
Preparation of enantiopure antimalarial agent (+)-mefloquine

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Description succincte
Anzeigen
-
-
Anzeigen
Résumé des résultats (Abstract)
Anzeigen
-
-
Anzeigen

Textes saisis


CatégorieTexte
Description succincte
(Allemand)
Preparation of enantiopure antimalarial agent (+)-mefloquine
Description succincte
(Anglais)
Preparation of enantiopure antimalarial agent (+)-mefloquine
Résumé des résultats (Abstract)
(Allemand)
Chiral amines are key components of pharmaceuticals but can be difficult, enviornmentally unfriendly, and|expensive to prepare. An excellent example of this problem is mefloquine, an anti-malerial drug currently|available only as a racemic mixture despite the fact that the (+)-enantiomer exhibits the desired activity while the side effects are associated with the (-)-enantiomer. This project will develop a new technology for separating the enantiomers of chiral amines from their mixtures on a kilogram scale. Working with Roche, this technology will be scaled up and used to prepare several hundred grams of enantiopure (+)-mefloquine, a quantity sufficient for early stage clinical trials.
Résumé des résultats (Abstract)
(Anglais)
Chiral amines are key components of pharmaceuticals but can be difficult, enviornmentally unfriendly, and|expensive to prepare. An excellent example of this problem is mefloquine, an anti-malerial drug currently|available only as a racemic mixture despite the fact that the (+)-enantiomer exhibits the desired activity while the side effects are associated with the (-)-enantiomer. This project will develop a new technology for separating the enantiomers of chiral amines from their mixtures on a kilogram scale. Working with Roche, this technology will be scaled up and used to prepare several hundred grams of enantiopure (+)-mefloquine, a quantity sufficient for early stage clinical trials.